The versatility of three-dimensional printed pharmaceuticals, relative to traditionally manufactured ones, could be leveraged for personalized treatment at the point of care, as well as being integrated into mass-manufacturing pipelines. Improvements in quality control and collaboration with regulatory bodies will pave the way to large-scale clinical translation.
- Liam Krueger
- Atheer Awad
- Amirali Popat
